StockData

Agenus vs Alector

AGEN and ALEC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and ALEC compare

Agenus and Alector are about the same size, with market caps of $283M and $286M.

Agenus grew revenue faster over the last twelve months (30.5% versus −82.9% for Alector).

Agenus scores higher on the StockData Score (3 against 1 for Alector), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENALEC
Size and price
Market cap$283M$286M
Share price$6.29$2.56
Change, 1 year45.3%106%
Change, 5 years−90.3%−87.1%
Beta (5Y)1.011.91
Employees81103
StockData Score
Total score3 (better)1
Valuation score1 (better)0
Growth score2 (better)0
Performance score00
Health score01 (better)
Dividend score00
Valuation
P/S2.1× (better)20.6×
EV/EBITDA7.0×–
FCF yield−34.8% (better)−55.4%
Growth
Revenue growth (TTM)30.5% (better)−82.9%
Revenue growth, 5Y average5.3% (better)−0.05%
Profitability
Gross margin99.5%–
Operating margin27.3% (better)−912%
Net margin–−850%
FCF margin−74.2% (better)−1143%
Return on equity–−385%
Financial health
Net debt / EBITDA0.28–
Interest coverage0.6×–
Current ratio0.345.26 (better)
Altman Z-score−16.54−7.35 (better)
Piotroski F-score–1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions31.7%85.8%
Held by insiders6.6%9.6%
Insider net buying, 12 months–−$1.0M
Short interest, % of float18.1%8.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.